Hydroxychloroquine (HCQ) PharmacoEpi 2026
Comprehensive Research Dataset • Evidence Triangulation • Pharmacovigilance
RESEARCH CUT-OFF: 4 NOVEMBER 2026 • GLOBAL & INDIAN PHARMACOVIGILANCE

Hydroxychloroquine: Comprehensive Pharmacoepidemiology Research Dataset

An interactive multi-source pharmacoepidemiological portal synthesizing approved and off-label indications, adverse drug reaction signals, patient-reported experiences, and evidence-based triangulation between clinical science and public attention.

Observed Data: Empirical numbers from trials & databases Estimated Data: Odds ratios, RORs & derived models Qualitative: Social media narratives & themes Evidence Assessment: GRADE-standardised ratings
Study Period
All Available Years through Nov 2026
Pillars Triangulated
Clinical Trials • Social Media • Search Data
Primary Databases
PubMed • FAERS • WHO VigiBase • PvPI
Epistemic Standard
Zero Invented Totals • Web-Verified
Total Indications
15
5 Approved • 10 Off-Label Evaluated
VigiBase Serious ICSRs
5,219
82.1% Female • 221 Fatal Cases (4.2%)
Tweets Analyzed
609,189
255,573 HCQ (42%) • JAMIA Study
Evidence Range
0 to 5
SLE 5/5 vs COVID-19 0/5 (Refuted)

Interactive Visual Analytics Dashboard

6 Real-Time Dynamic Charts
1. The Epistemic Disconnect Matrix
Clinical Evidence Strength (0–5) vs. Public & Search Visibility Index (0–100)
Triangulation
Red bubble: COVID-19 disconnect (0/5 evidence vs 98% attention) Green: SLE & RA
2. WHO VigiBase Serious ADR Distribution
Breakdown across 5,219 serious Individual Case Safety Reports (2010–2019)
VigiBase
Hypersensitivity (23.5%), Arthralgia (16.9%), GI (13.9%), Retinal (6.7%) 221 Deaths (4.2%)
3. US FAERS Disproportionality Signals (ROR)
Reporting Odds Ratios comparing target ADR odds vs all other drugs in FAERS
FAERS ROR
Cardiomyopathy ROR: 29.0 • QT Prolongation: 4.5 • Retinopathy: 3.90 Signal threshold: ROR > 2.0
4. Twitter Public Perception & Tweet Volume
JAMIA NLP study: 609,189 tweets comparing 4 COVID-19 repurposed medicines
Social NLP
HCQ: 255,573 mentions (42%) • 53.04% supportive attitude Source: JAMIA 2022
5. Retinal Toxicity 20-Year Risk Trajectory
Projected cumulative retinopathy rate: Low Dose (≤5 mg/kg) vs High Dose (>5 mg/kg)
AAO / Marmor
Inflection point: Risk accelerates beyond 5–10 years & >5 mg/kg Melles & Marmor (n=2,361)
6. Key Clinical Trial Primary Outcomes
Empirical outcomes from RECOVERY (Mortality), JOQUER (Response), & Sarcoidosis
Clinical Trials
RECOVERY: 27% HCQ vs 25% Usual Care (RR 1.09) • JOQUER: 17.9% vs 17.2% Empirical Trials

The Six Core Epidemiological Research Questions

Methodological Architecture
RQ-1 • Regulatory Label Label Analysis
What are the approved indications for HCQ?

Evaluating US DailyMed, FDA, and international approvals for malaria, SLE, RA, and discoid lupus.

RQ-2 • Clinical Practice Off-Label Scope
Which additional conditions are being treated off-label?

Mapping clinical applications in Sjögren's, APS, sarcoidosis, lichen planus, dermatomyositis, and COVID-19.

RQ-3 • GRADE Evidence Trial Rigor
How strong is the clinical evidence supporting each use?

Applying modified GRADE scoring (0 to 5) from randomized trials (JOQUER, RECOVERY) and systematic reviews.

RQ-4 • Safety Profile Pharmacovigilance
What ADRs are documented in clinical trials and PV databases?

Analyzing WHO VigiBase, FAERS disproportionality signals (RORs), and Indian PvPI prophylaxis monitoring.

RQ-5 • Patient Voice Social Listening
What benefits and adverse effects do patients discuss online?

Investigating 609k Twitter stances and qualitative Reddit SLE patient threads on eye exams and tolerability.

RQ-6 • Triangulation Epistemic Disconnect
Does public interest correspond with actual clinical evidence?

Evaluating the misalignment between search queries, media hype (+109% surge), and negative clinical trials.

Dataset A: Approved & Off-Label Indications Master

5 Approved 10 Off-Label
Filter:
ID Indication & Clinical Intent Status Evidence Score Key Evidence / Primary Trial Action

Key Published Clinical Trials & Systematic Reviews

Negative Primary RCT

Sjögren's Syndrome: JOQUER Trial

Gottenberg et al., JAMA 2014 (n=120)
Score: 2/5

Double-blind RCT comparing HCQ 400 mg/day vs placebo over 24 weeks. Primary endpoint: ≥30% improvement in 2 of 3 major symptoms (dryness, pain, fatigue).

Pharmacoepidemiology Lesson: Despite failing its primary outcome, HCQ remains widely prescribed off-label for Sjögren's due to historical clinical habit and systemic immunomodulatory rationale.
Real-World Cohort

Sarcoidosis: 2024 Observational Study

PMC11472668, 2024 (n=60)
Score: 2/5

Evaluating 60 patients with cutaneous (22%) and musculoskeletal (75%) sarcoidosis. 55% sustained therapy beyond 24 weeks; 18.3% discontinued due to ADRs.

Key Subgroup Insight: Cutaneous lesions showed significantly superior retention (85% vs 47%, P=0.02), demonstrating indication-specific utility within off-label phenotypes.
Definitive Negative RCT

COVID-19: RECOVERY Trial

NEJM 2020 (n=4,716 hospitalized patients)
Score: 0/5

Large pragmatic open-label randomized trial. 1,561 patients assigned to HCQ vs 3,155 to usual care. Evaluated 28-day mortality, hospital stay, and mechanical ventilation.

Trial Conclusion: No reduction in mortality (27% vs 25%, RR 1.09). Lower probability of discharge alive. FDA EUA revoked June 15, 2020; WHO Solidarity trial arm halted.

Interactive Retinal Toxicity Risk Stratifier & AAO 2025 Screening Protocol

AAO 2025 Revised Guidelines Melles & Marmor 2014 Model

Patient Exposure & Clinical Risk Factors

Calculated Exposure & Risk Stratification

Retinopathy Risk Category
Low Baseline Risk
Based on Melles & Marmor 2,361-patient cohort outcomes.
Dose / Real Body Weight
6.67 mg/kg/day
Target: ≤ 5.0 mg/kg/day
Estimated Cumulative Dose
877 g
High risk threshold: >1000g
AAO 2025 Screening Action:
Baseline exam required in year 1.
Recommended Visual Field Protocol:
Standard Non-Asian: 10-2 Visual Field + SD-OCT
Reference: Melles RB, Marmor MF. JAMA Ophthalmol. 2014;132(12):1453-60 • AAO 2025 Revised Clinical Statement.

Interactive 2×2 Pharmacovigilance Disproportionality Calculator (ROR)

The Reporting Odds Ratio compares the odds of a specific target adverse event occurring with HCQ versus all other medicinal products in the pharmacovigilance safety repository:

Database Stratum Target Adverse Event (e.g., Cardiomyopathy) All Other Reported Reactions
Hydroxychloroquine Reports Cell a (Cases) Cell b (Other HCQ ADRs)
All Other Drugs in Database Cell c (Other drugs target) Cell d (Other drugs other ADRs)
Formula: ROR = (a × d) / (b × c) | SE(ln ROR) = √(1/a + 1/b + 1/c + 1/d)
Calculated Reporting Odds Ratio
29.00
95% CI: [23.32 — 36.08]
Disproportionate Signal Detected (ROR ≥ 2.0)

An ROR of 29.0 indicates that cardiomyopathy was reported 29 times more frequently with HCQ compared to the background spontaneous reporting rate across all other medications in FAERS.

US FAERS Disproportionality Signals & Reporting Odds Ratios (ROR)

FAERS 1998–2019
Target Adverse Drug Reaction Database Domain Reported Cases Reporting Odds Ratio (ROR) 95% Confidence Interval Signal Intensity

Indian Pharmacovigilance Profile (PvPI & MoHFW Prophylaxis Safety Surveillance)

India National PV

A. Prospective Healthcare Worker Safety Assessment (n=1,323)

Observed adverse events in high-risk healthcare workers receiving prophylaxis under MoHFW national protocol:

Nausea 8.9% (118 cases)
Abdominal Pain 7.3% (97 cases)
Cardiovascular Effects 1.9% (25 cases)
Hypoglycaemia 1.7% (22 cases)
Vomiting 1.5% (20 cases)

B. National PvPI Spontaneous Prophylaxis Reports (n=214)

Spontaneous individual case safety reports received by the Pharmacovigilance Programme of India (PvPI):

7
Serious ICSRs
3
QT Prolongation
Critical Epidemiological Rule: Do NOT add the 214 spontaneous PvPI reports to the 1,323 assessed healthcare workers. One is a voluntary spontaneous reporting repository, the other is an active assessed cohort.

Consolidated 15 ADR Master Dictionary & MedDRA Coding Taxonomy

Standard Coding Dictionary
ADR ID Preferred Term (PT) Organ System MedDRA System Organ Class (SOC) Seriousness Potential Key Research Variables
ADR-01NauseaGastrointestinalGastrointestinal disordersUsually non-seriousFrequency, meal timing, duration
ADR-02VomitingGastrointestinalGastrointestinal disordersVariable (dehydration)Volume, oral intake maintenance
ADR-03DiarrhoeaGastrointestinalGastrointestinal disordersVariableBristol stool chart, non-infectious
ADR-04Maculopapular rashDermatologicalSkin & subcutaneousVariableMorphology, onset post-initiation
ADR-05PruritusDermatologicalSkin & subcutaneousUsually non-seriousSun exposure, pigmentation, duration
ADR-06HyperpigmentationDermatologicalSkin & subcutaneousUsually non-seriousCumulative exposure, shins/palate
ADR-07RetinopathyOphthalmologicalEye disordersSerious / IrreversibleDaily dose (mg/kg), duration, SD-OCT, VF
ADR-08QT prolongationCardiacCardiac disordersSeriousBaseline QTc, ΔQTc, concomitant QT drugs
ADR-09Torsades de pointesCardiacCardiac disordersLife-threateningAzithromycin co-medication, electrolytes
ADR-10CardiomyopathyCardiacCardiac disordersSerious / DisablingCumulative dose, hypertrophy, CMR/biopsy
ADR-11HypoglycaemiaMetabolicMetabolism & nutritionPotentially seriousBlood glucose, antidiabetic co-drugs
ADR-12Cytopenia (Leukopenia, etc.)HaematologicalBlood & lymphatic systemPotentially seriousComplete blood count (CBC)
ADR-13Myopathy (Vacuolar)MusculoskeletalMusculoskeletal & connectivePotentially seriousProximal weakness, serum CK
ADR-14Peripheral neuropathyNeurologicalNervous systemVariableElectromyogram (EMG), sensory/motor
ADR-15Neuropsychiatric reactionsPsychiatricPsychiatric disordersVariablePsychosis, agitation, sleep disturbance

Google Trends & Media Exposure Dynamics (2019–2022)

+109% Search Surge per SD Media
2019 Baseline Search Index
0.5 / 100
Standard Deviation: 2.0
Pandemic Peak Search Index
2.5 / 100
Peak: 100.0 on 20 March 2020
Media News Broadcast Coverage
0.08% vs 0.0006%
133-fold increase over baseline

Regression modeling by Englund et al. revealed that a one-standard-deviation increase in news media coverage was associated with a 109% increase in Google search interest (95% CI: 101% – 118%). Public search interest closely tracked political and media announcements rather than peer-reviewed clinical trial releases.

Reddit Patient Experience Themes in Systemic Lupus (PMC 2026 Study)

4,633 Posts / 2,603 Filtered

Analysis of 2,603 patient narratives across 10 SLE Reddit communities, extracted via natural language processing and large language model qualitative thematic coding:

Methodological Guardrails: What Social Media CAN and CANNOT Conclude

Dataset D: Evidence vs Public Attention Triangulation Visualizer

The Epistemic Disconnect

This interactive quadrant visualizes the relationship between Clinical Evidence Strength (modified GRADE score 0 to 5) on the horizontal axis and Public & Search Visibility Index (0 to 100) on the vertical axis across all evaluated HCQ indications.

Zone 1: Extreme Hype / Epistemic Disconnect Low/Zero clinical trial evidence with peak public & media enthusiasm (Exemplar: COVID-19).
Zone 2: Grounded Standard of Care High clinical evidence matched by robust clinical guideline and patient interest (Exemplars: SLE, RA).
Zone 3: Quietly Established Anti-Infective Proven clinical efficacy for sensitive parasites, but minimal viral public hype (Exemplar: Malaria).
Zone 4: Research Frontier / Habitual Off-Label Moderate clinical use driven by clinical habit or small observational cohorts (Exemplars: Sjögren's, Sarcoidosis, APS).

Triangulation Master Matrix

Indication Clinical Evidence Google Search Visibility Social Media Stance Disconnect Classification Final Assessment

Dataset E: Complete 28-Field Variable Dictionary

Quantitative Dataset Architecture

Standardized data coding dictionary for building retrospective patient cohorts, pharmacovigilance registries, or SPSS/R/Python analytical pipelines:

Filter Type:
No. Variable Identifier Data Type Coding / Permitted Values Epidemiological Definition

Organ-Specific Deep Clinical Sub-Modules

Retinal Module

Ophthalmological Surveillance

  • weight_kg: Actual real body weight in kg (≤5.0 mg/kg target)
  • cumulative_dose_g: Lifetime grams consumed (>1000g high risk)
  • egfr_ml_min: Estimated GFR (<60 mL/min clearance deficit)
  • tamoxifen_concomitant: Tamoxifen co-therapy (OR 4.59)
  • oct_finding: Normal, 'Flying Saucer' sign, photoreceptor thinning
  • humphrey_vf_pattern: 10-2 paracentral vs 24-2/30-2 pericentral (Asian)
Cardiac Module

Cardiovascular Safety Sub-Module

  • baseline_qtc_ms: Pre-treatment Bazett/Fridericia corrected QTc
  • followup_qtc_ms: On-treatment QTc (>500 ms or >60 ms prolongation)
  • concomitant_qt_drugs: Azithromycin, antiarrhythmics, SSRIs
  • echocardiogram_lvef: LV ejection fraction % (hypertrophy/CMR)
  • endomyocardial_biopsy: Curvilinear bodies on electron microscopy
Derm Module

Cutaneous Adverse Event Sub-Module

  • morphology: Maculopapular, lichenoid, pustular (AGEP), bullous
  • body_surface_area_percent: Percentage BSA involved
  • mucosal_involvement: Oral, ocular, or genital mucosal erosions
  • skin_pigmentation_site: Blue-grey shins, hard palate, nail beds

Part G: The Seven Core Pharmacoepidemiological Findings

Part H: Research Limitations & Mitigation Framework

Methodological Rigor
Methodological Limitation Potential Impact on Observed Results Implemented Mitigation Strategy

Part I: Primary Research Workbook (Ready-to-Build 6-Sheet Structure)

Select any of the six standardized project sheets below to inspect structured records, copy tabular data, or export directly to CSV for spreadsheet modeling:

Sources & Evidence Library (#sources)

16 of 16 Sources Displayed

Primary authoritative literature, randomized controlled trials, global pharmacovigilance repositories, clinical guidelines, and social infodemiology studies grounding this pharmacoepidemiological research dataset.

Evidence Hierarchy Pyramid (Click to Filter by Tier):
2
Level 1: RCTs
3
Level 2: Reviews
2
Level 3: Cohorts
2
Level 4: Guidelines
3
Level 5: PV DBs
3
Level 6: Social/Search
1
Regulatory Label
Reference Manager Export: Download formatted citations for Zotero, Mendeley, EndNote, or Overleaf